Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1

Conditions

Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Carcinoma 1

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × belinostat × Endocrine × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00926640 2018-10-19

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
EndocrineThoracic

Carcinoma, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡